Improving opioid agonist care continuation, meta-analysis
Improving opioid agonist care continuation remains to be a challenge for many community based addiction treatment organizations. Research into effective strategies has used both randomized and non-randomized designs. Is there any difference in treatment dropout between these different study types? (more…)
Finding good endpoints for diagnostic test accuracy reviews on substance use
Diagnostic test accuracy reviews increasingly are being used in substance use research, yet the majority of the studies considered in these reviews do not account appropriately for the primary endpoints of interest. (more…)
Can prescribers avoid contributing to opioid use disorder?
A 21 y/o has surgery for a condition expected to improve. He fills a discharge prescription for 5 days of an opioid at a standard dose. At 1-week follow-up with his family doctor for suture removal, he describes ongoing pain. Can prescribers avoid contributing to opioid use disorder? Is a renewal of opioid appropriate, potentially dangerous, or both? Read more …
Can prescribers avoid contributing to opioid use disorder?
Why Cochrane collaboration makes strongest researchers
So what has the Cochrane membership done for me? Inspired by Dr Jeremy Grimshaw’s question: “So what has the Cochrane Collaboration ever done for us?” I submit a report card, a mosaic of my previous blogs, on my first 10 years with Cochrane.
Scoping the needs of early career addiction specialists, Protocol
What are the training needs of newly trained professionals working in addiction medicine around the world? Do they get enough and appropriate training to treat people who live with addictions? A new study protocol plans to answer these questions. (more…)